Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Chronic belching is an underappreciated side effect of GLP-1 medications, but a new study suggests an unexpected remedy: singing. A randomized controlled trial found that structured singing therapy outperformed standard diaphragmatic breathing in reducing symptoms of supragastric belching — and patients actually enjoyed it. Experts say the findings are clinically relevant, though more research is needed.
Chronic supragastric belching — frequent air intake and expulsion that never reaches the stomach — is a lesser-known but quality-of-life-disrupting side effect increasingly seen in patients on GLP-1 receptor agonists. One study of semaglutide reported belching in about 11% of participants, and clinicians note that distinguishing medication-induced belching from a behavioral disorder can be tricky in primary care settings.
A new multicenter randomized controlled trial published in Clinical Gastroenterology and Hepatology offers a fresh approach: structured singing therapy. Researchers enrolled 72 adults with supragastric belching and compared singing against diaphragmatic breathing — the current first-line treatment. Singing came out on top, with better symptom relief, sustained results at one month, and notably higher patient engagement.
By the Numbers:
Why it matters: As GLP-1 prescriptions surge, primary care providers are fielding more GI complaints. Singing therapy's higher adherence rates — especially among older adults and those with severe symptoms — make it a promising, low-risk addition to the clinical toolkit, though experts recommend a multidisciplinary approach involving gastroenterology, behavioral therapy, and speech-language pathology.
